30 分鐘

006 Using Genomics to Accelerate Drug Development BC Platforms Podcast

    • 生命科學

Today's episode will focus on the topic of using genomics to accelerate drug development. 
Our host is Tõnu Esko, BC Platforms SAB Chairman and Vice Director of the Institute of Genomics University of Tartu, where he also holds a Professor of Human Genomics position. He is head of the Estonian Biobank Innovation Center and focuses on public private partnerships and innovation transfer. Dr. Esko is also a research scientist at the Broad Institute of Harvard at MIT. He acts as one of the senior leaders for Estonian personalized medicine programs and serves as a scientific advisor for several companies. 
Our guest today is Iris Grossman, on the leading edge of Personalized Medicine, Big Data Analytics and Biotech R&D for 20 years. She is Acting CSO of Amide and advises other biotech in her field of expertise. She has held leadership positions and or consulted for top big pharma GSK, Eli Lilly, Takeda and Teva, where she was VP Head of early stage development, startup and consultancies. She specializes in leveraging high dimensional genomic insights and E-health as engines of therapeutic discovery, development and Lifecycle Management across a wide range of modalities and therapeutic areas. Iris also serves as SAB member of BC platforms, Tipa Biobank, Eleven Therapeutics and CGRP Diagnostics. She earned her B.Sc. in Medicine at the Technion, and a PhD in Medicine, Population Genomics and Pharmacogenomics for the Technion, co-mentored with the Weitzman Institute. Next, she was a postdoc fellow in Personalized Medicine and Population Genomics at Duke University.
What is covered:
- The benefits of using big data in drug discovery
- Specific examples of how the genetics could be helpful in the drug discovery, such as the contribution of human genetics and genomics to fighting COVID
- The recommendations to stakeholders for collaborating within the industry for the sake of innovation 
- How biobanks can potentially act as middlemen for this new type of collaboration
Resources:
- The Institute of Genomics, University of Tartu https://genomics.ut.ee/en
- The Estonian Biobank https://genomics.ut.ee/en 
- Amide Technologies https://www.amidetech.com/
- GSK https://www.gsk.com/
- Eli Lilly https://www.lilly.com/
- Takeda https://www.takeda.com/
- Teva Pharmaceutical https://www.tevapharm.com/
- Tipa Biobank https://www.ksminnovation.com/biobank
- Eleven Therapeutics https://eleventx.com/
- CGRP Diagnostics http://cgrpdiagnostics.com/
Connect with Iris Grossman:
- https://www.linkedin.com/in/irisgrossman/
Connect with Dr. Tõnu Esko: 
- https://www.linkedin.com/in/tõnu-esko-24511524/ 
Connect with BC Platforms: 
- https://www.bcplatforms.com 
- https://www.linkedin.com/company/bc-platforms/ 
- sales@bcplatforms.com 

Today's episode will focus on the topic of using genomics to accelerate drug development. 
Our host is Tõnu Esko, BC Platforms SAB Chairman and Vice Director of the Institute of Genomics University of Tartu, where he also holds a Professor of Human Genomics position. He is head of the Estonian Biobank Innovation Center and focuses on public private partnerships and innovation transfer. Dr. Esko is also a research scientist at the Broad Institute of Harvard at MIT. He acts as one of the senior leaders for Estonian personalized medicine programs and serves as a scientific advisor for several companies. 
Our guest today is Iris Grossman, on the leading edge of Personalized Medicine, Big Data Analytics and Biotech R&D for 20 years. She is Acting CSO of Amide and advises other biotech in her field of expertise. She has held leadership positions and or consulted for top big pharma GSK, Eli Lilly, Takeda and Teva, where she was VP Head of early stage development, startup and consultancies. She specializes in leveraging high dimensional genomic insights and E-health as engines of therapeutic discovery, development and Lifecycle Management across a wide range of modalities and therapeutic areas. Iris also serves as SAB member of BC platforms, Tipa Biobank, Eleven Therapeutics and CGRP Diagnostics. She earned her B.Sc. in Medicine at the Technion, and a PhD in Medicine, Population Genomics and Pharmacogenomics for the Technion, co-mentored with the Weitzman Institute. Next, she was a postdoc fellow in Personalized Medicine and Population Genomics at Duke University.
What is covered:
- The benefits of using big data in drug discovery
- Specific examples of how the genetics could be helpful in the drug discovery, such as the contribution of human genetics and genomics to fighting COVID
- The recommendations to stakeholders for collaborating within the industry for the sake of innovation 
- How biobanks can potentially act as middlemen for this new type of collaboration
Resources:
- The Institute of Genomics, University of Tartu https://genomics.ut.ee/en
- The Estonian Biobank https://genomics.ut.ee/en 
- Amide Technologies https://www.amidetech.com/
- GSK https://www.gsk.com/
- Eli Lilly https://www.lilly.com/
- Takeda https://www.takeda.com/
- Teva Pharmaceutical https://www.tevapharm.com/
- Tipa Biobank https://www.ksminnovation.com/biobank
- Eleven Therapeutics https://eleventx.com/
- CGRP Diagnostics http://cgrpdiagnostics.com/
Connect with Iris Grossman:
- https://www.linkedin.com/in/irisgrossman/
Connect with Dr. Tõnu Esko: 
- https://www.linkedin.com/in/tõnu-esko-24511524/ 
Connect with BC Platforms: 
- https://www.bcplatforms.com 
- https://www.linkedin.com/company/bc-platforms/ 
- sales@bcplatforms.com 

30 分鐘